Key Takeaways
- Liraglutide was the first GLP-1 approved for weight management.
- Tirzepatide is administered once weekly, while liraglutide requires a daily subcutaneous injection.
- Tirzepatide is associated with better long-term treatment adherence and delivers greater weight-loss results.
- Liraglutide remains a key option for adolescents aged 12 and older, as it’s one of the few GLP-1s that have FDA weight-management approval for this group.
The headlines tend to focus on the newest glucagon-like peptide-1 (GLP-1) medications. But older GLP-1s still deliver solid results and might be the best fit for some people.
Back in 2014, liraglutide was the first GLP-1 medication approved for weight management in the U.S. A decade later, tirzepatide has built on its path, almost tripling liraglutide’s weight loss results in clinical trials with a dual-receptor mechanism. But more weight loss doesn’t always mean better.
This article compares tirzepatide versus liraglutide to give you a better understanding of both. Read on to learn how they work, how they compare on effectiveness and side effects, and who each one is best suited for.
How tirzepatide vs. liraglutide work: Single vs. dual receptor agonism
After you eat, your body produces GLP-1. This hormone slows your stomach’s emptying, boosts insulin release, lowers glucagon when glucose is high, and blunts your appetite. Together, these effects control blood sugar and reduce how much you eat. Leveraging this, researchers have developed GLP-1 medications that activate GLP-1 receptors for longer than your own body’s hormone to treat type 2 diabetes and aid weight management efforts.
Liraglutide (sold under the brand names Saxenda® and Victoza®) was one of the earliest GLP-1s in the market, and it was the first one approved for weight management. It activates the GLP-1 pathway with a half-life of roughly 13 hours. That means you have to inject it every day.
Given the success of GLP-1s, researchers have worked hard to create longer-lasting and more effective GLP-1s. Tirzepatide (active ingredient in Zepbound® and Mounjaro®) is the result of that process. In addition to the GLP-1 pathway, tirzepatide activates the receptors of a second hormone called glucose-dependent insulinotropic polypeptide (GIP). GIP makes your cells respond to insulin more effectively and influences how your body processes and stores energy as fat.
Here’s a closer look at the difference between these two GLP-1s.
Are tirzepatide and liraglutide effective for weight loss?
Both tirzepatide and liraglutide produce meaningful weight loss when you combine them with a reduced-calorie diet and exercise. But when it comes to effectiveness, tirzepatide stands out.
Participants at the highest dose of tirzepatide in the SURMOUNT-1 trial lost an average of 20.9% of their body weight over 72 weeks. Even the lowest dose, 5 mg, produced a 15% of average loss. Around 9 in 10 participants lost at least 5%, and more than half of people at the highest dose lost 20% or more.
Clinical evidence for liraglutide weight loss comes from the SCALE Obesity and Prediabetes trial. Adults taking liraglutide daily lost an average of 7.4% of their body weight over 56 weeks, compared to 3% with placebo. About 62% of participants lost at least 5% of their starting weight, and roughly a third lost 10% or more.
In both cases, weight loss usually began during the first weeks of treatment and built throughout the course of the trials—though weight plateaus are common and don’t necessarily mean that the medication stopped working. Individual results varied according to dose, the person’s lifestyle, and each body’s reaction to the medication.
The trials involved different populations, timelines, and study design, so these numbers don’t work as a head-to-head comparison. But the pattern holds across indirect comparisons: Tirzepatide’s dual-pathway mechanism produces two to three times the weight loss of liraglutide’s single pathway.
Side effects and safety of tirzepatide vs. liraglutide
Due to the delayed digestion mechanism these two medications share, their most common side effects are gastrointestinal (GI). These reactions tend to be worse during dose escalation, while your body is adjusting, and fade over time. These reactions, however, happen more often with liraglutide than with tirzepatide:
Both medications carry some serious warnings on their labels:
- Thyroid C-cell tumors: In animal studies, both drugs caused thyroid tumors in rodents. We still don’t know if this is the case for humans as well. But as a prevention measure, these medications are off the table for anyone with a personal or family history of medullary thyroid carcinoma or a rare genetic mutation called MEN2.
- Pancreatitis: As both medications act on the pancreas to regulate insulin, there’s a small risk of pancreatic inflammation. In trials, it amounted to 0.3% with liraglutide and 0.2% with tirzepatide.
- Gallbladder disease: Your liver releases more cholesterol into bile when you lose weight quickly. This cholesterol can crystallize into gallstones, generating gallstone inflammation.
- Acute kidney injury: The nausea, vomiting, and diarrhea these medications cause can lead to dehydration, which reduces blood flow to the kidneys and impairs their function.
- Heart rate: Both liraglutide and tirzepatide can raise your resting heart rate slightly. Liraglutide's effect is more pronounced, and its label requires regular monitoring.
Tirzepatide vs. liraglutide cost and insurance
Before you start with either medication, make sure the cost is manageable. Pricing depends on your insurance plan, dose, and the savings programs you qualify for.
Here’s how Saxenda® versus Zepbound® compare on cost and access.
Some employer plans exclude weight management drugs entirely. If they don’t, you probably need prior authorization to get coverage for either medication. That means your provider submits documentation of your diagnosis and medical history, and your insurance decides whether to approve the prescription in a process that can take days to weeks. Also, many plans ask you to try a lower-cost medication—like Contrave® or Qsymia®—first.
Who should use tirzepatide vs. liraglutide?
Neither of these medications is a one-size-fits-all. Your provider will recommend one based on your weight, health history, and goals. Here are a few factors to keep in mind before picking one of these medications.
Tirzepatide may be a better fit if:
- You’re an adult.
- You have more weight to lose.
- You have moderate-to-severe obstructive sleep apnea (OSA).
- You prefer fewer injections.
- You value dosing flexibility. If you miss a dose, you have a four-day window to take it before skipping to the next week.
- You have insurance coverage for weight loss medications or can manage the out-of-pocket costs.
Liraglutide may be a better fit if:
- You don’t have insurance coverage for weight loss medication and are paying your treatment out of pocket.
- Your insurance plan requires you try a lower-cost option before approving tirzepatide.
- You are under 18 years old.
- You have safety considerations that make a shorter-acting medication preferable. Liraglutide clears your system in about a day, compared to tirzepatide’s week-long action.
- You can commit to a daily injection schedule.
Make an informed decision with Maven Clinic
Is liraglutide better than tirzepatide? The answer depends on what you’re looking for. Tirzepatide produces two to three times more weight loss and requires just one injection per week. Liraglutide offers generic availability and a lower price. The best choice for your case depends on your coverage, health history, and main goal.
If you’re weighing these and other GLP-1 options, reach out to Maven Clinic. Our GLP-1 program connects you with specialists who build an evidence-based plan that suits your needs best.
FAQ
No. The Saxenda® label explicitly states that it shouldn’t be used with any other GLP-1 treatment.
There’s no maximum treatment duration. Liraglutide is approved for long-term chronic weight management, and many people stay on it indefinitely. The Saxenda® label does require a check-in at 16 weeks. Your provider might recommend stopping if you haven’t lost 4% of your body weight by then.
Neither has been shown to be significantly safer than the other. They share the same boxed warning about thyroid C-cells tumors in rodents, the same contraindications, and overlap on side effects.
Side effects of tirzepatide for weight loss are milder, but the differences are generally minimal. Liraglutide causes more nausea (39% versus 25–29%) and has a higher treatment discontinuation rate (9.8% versus 4.8–6.7%).
Yes, based on clinical trial data. In the SURMOUNT-1 trial, tirzepatide produced 15–21% average weight loss at 72 weeks, much higher than semaglutide’s 7.4% at 56 weeks in the SCALE trial. These were separate studies with different populations and designs, but the patterns hold across indirect analyses.











